"In vitro" correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate.

Cristiana BulatoC NovembrinoM Boscolo AnzolettiL SpieziaS GavassoC BerbenniGiuseppe TagarielloC FarinaI NardiniE CampelloFlora PeyvandiP Simioni

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2018)

The novel plasma-derived FV concentrate was effective to correct "in vitro" severe FV deficiency in patients. The optimal FV concentration to fully normalize both global clotting times and thrombin generation parameters using the novel plasma-derived FV concentrate was 25 IU/dL.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
early onset
peritoneal dialysis
drug induced
patient reported outcomes